{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:18:06Z","timestamp":1793420286986,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ITI Foundation Scholarship"},{"name":"Osteology Foundation Research Scholarship"},{"name":"UCB Pharma\/Amgen Inc."},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH\/NIDCR U24 DE026915"],"award-info":[{"award-number":["NIH\/NIDCR U24 DE026915"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Destruction of the alveolar bone in the jaws can occur due to periodontitis, trauma or following tumor resection. Common reconstructive therapy can include the use of bone grafts with limited predictability and efficacy. Romosozumab, approved by the FDA in 2019, is a humanized sclerostin-neutralizing antibody (Scl-Ab) indicated in postmenopausal women with osteoporosis at high risk for fracture. Preclinical models show that Scl-Ab administration preserves bone volume during periodontal disease, repairs bone defects surrounding dental implants, and reverses alveolar bone loss following extraction socket remodeling. To date, there are no studies evaluating Scl-Ab to repair osseous defects around teeth or to identify the efficacy of locally-delivered Scl-Ab for targeted drug delivery. In this investigation, the use of systemically-delivered versus low dose locally-delivered Scl-Ab via poly(lactic-co-glycolic) acid (PLGA) microspheres (MSs) was compared at experimentally-created alveolar bone defects in rats. Systemic Scl-Ab administration improved bone regeneration and tended to increase cementogenesis measured by histology and microcomputed tomography, while Scl-Ab delivered by MSs did not result in enhancements in bone or cemental repair compared to MSs alone or control. In conclusion, systemic administration of Scl-Ab promotes bone and cemental regeneration while local, low dose delivery did not heal periodontal osseous defects in this study.<\/jats:p>","DOI":"10.1038\/s41598-020-73026-y","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T10:04:13Z","timestamp":1601546653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Sclerostin antibody stimulates periodontal regeneration in large alveolar bone defects"],"prefix":"10.1038","volume":"10","author":[{"given":"Yao","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Kauffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea V.","family":"Sarment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James V.","family":"Sugai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Schmiedeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Holdsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Kostenuik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William V.","family":"Giannobile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,1]]},"reference":[{"issue":"Suppl 2","key":"73026_CR1","doi-asserted-by":"publisher","first-page":"S467","DOI":"10.1002\/jbmr.5650081307","volume":"8","author":"MK Jeffcoat","year":"1993","unstructured":"Jeffcoat, M. K. Bone loss in the oral cavity. J. Bone Miner. Res. 8(Suppl 2), S467-473. https:\/\/doi.org\/10.1002\/jbmr.5650081307 (1993).","journal-title":"J. Bone Miner. Res."},{"key":"73026_CR2","doi-asserted-by":"publisher","first-page":"175873601245654","DOI":"10.1177\/1758736012456543","volume":"3","author":"S Hansson","year":"2012","unstructured":"Hansson, S. & Halldin, A. Alveolar ridge resorption after tooth extraction: a consequence of a fundamental principle of bone physiology. J. Dent Biomech. 3, 1758736012456543. https:\/\/doi.org\/10.1177\/1758736012456543 (2012).","journal-title":"J. Dent Biomech."},{"issue":"Suppl 5","key":"73026_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0501.2011.02375.x","volume":"23","author":"WL Tan","year":"2012","unstructured":"Tan, W. L., Wong, T. L., Wong, M. C. & Lang, N. P. A systematic review of post-extractional alveolar hard and soft tissue dimensional changes in humans. Clin. Oral Implants Res. 23(Suppl 5), 1\u201321. https:\/\/doi.org\/10.1111\/j.1600-0501.2011.02375.x (2012).","journal-title":"Clin. Oral Implants Res."},{"key":"73026_CR4","doi-asserted-by":"publisher","first-page":"e1800457","DOI":"10.1002\/adhm.201800457","volume":"7","author":"C Vaquette","year":"2018","unstructured":"Vaquette, C. et al. Tissue engineered constructs for periodontal regeneration: current status and future perspectives. Adv. Healthc. Mater. 7, e1800457. https:\/\/doi.org\/10.1002\/adhm.201800457 (2018).","journal-title":"Adv. Healthc. Mater."},{"key":"73026_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/0022034515618887","volume":"95","author":"L Larsson","year":"2016","unstructured":"Larsson, L. et al. Regenerative medicine for periodontal and peri-implant diseases. J. Dent. Res. 95, 255\u2013266. https:\/\/doi.org\/10.1177\/0022034515618887 (2016).","journal-title":"J. Dent. Res."},{"key":"73026_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003607.pub3","author":"M Esposito","year":"2008","unstructured":"Esposito, M., Grusovin, M. G., Kwan, S., Worthington, H. V. & Coulthard, P. Interventions for replacing missing teeth: bone augmentation techniques for dental implant treatment. Cochrane Database Syst Rev https:\/\/doi.org\/10.1002\/14651858.CD003607.pub3 (2008).","journal-title":"Cochrane Database Syst Rev"},{"key":"73026_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.coms.2011.04.004","volume":"23","author":"AS Herford","year":"2011","unstructured":"Herford, A. S. & Dean, J. S. Complications in bone grafting. Oral Maxillofac. Surg. Clin. North. Am. 23, 433\u2013442. https:\/\/doi.org\/10.1016\/j.coms.2011.04.004 (2011).","journal-title":"Oral Maxillofac. Surg. Clin. North. Am."},{"key":"73026_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1210\/er.2011-1060","volume":"33","author":"HZ Ke","year":"2012","unstructured":"Ke, H. Z., Richards, W. G., Li, X. & Ominsky, M. S. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr. Rev. 33, 747\u2013783. https:\/\/doi.org\/10.1210\/er.2011-1060 (2012).","journal-title":"Endocr. Rev."},{"key":"73026_CR9","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","volume":"19","author":"KE Poole","year":"2005","unstructured":"Poole, K. E. et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19, 1842\u20131844. https:\/\/doi.org\/10.1096\/fj.05-4221fje (2005).","journal-title":"FASEB J."},{"key":"73026_CR10","doi-asserted-by":"publisher","first-page":"19489","DOI":"10.1074\/jbc.M110.190330","volume":"286","author":"O Leupin","year":"2011","unstructured":"Leupin, O. et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J. Biol. Chem. 286, 19489\u201319500. https:\/\/doi.org\/10.1074\/jbc.M110.190330 (2011).","journal-title":"J. Biol. Chem."},{"key":"73026_CR11","doi-asserted-by":"publisher","first-page":"E478","DOI":"10.1073\/pnas.1409857112","volume":"112","author":"X Tu","year":"2015","unstructured":"Tu, X. et al. Osteocytes mediate the anabolic actions of canonical Wnt\/beta-catenin signaling in bone. Proc. Natl. Acad. Sci. USA 112, E478-486. https:\/\/doi.org\/10.1073\/pnas.1409857112 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73026_CR12","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1359\/JBMR.050210","volume":"20","author":"JR Hens","year":"2005","unstructured":"Hens, J. R. et al. TOPGAL mice show that the canonical Wntsignaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J. Bone Miner. Res. 20, 1103\u20131113. https:\/\/doi.org\/10.1359\/JBMR.050210 (2005).","journal-title":"J. Bone Miner. Res."},{"key":"73026_CR13","doi-asserted-by":"publisher","first-page":"19883","DOI":"10.1074\/jbc.M413274200","volume":"280","author":"X Li","year":"2005","unstructured":"Li, X. et al. Sclerostin binds to LRP5\/6 and antagonizes canonical Wntsignaling. J. Biol. Chem. 280, 19883\u201319887. https:\/\/doi.org\/10.1074\/jbc.M413274200 (2005).","journal-title":"J. Biol. Chem."},{"key":"73026_CR14","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/jbmr.474","volume":"26","author":"AH van Lierop","year":"2011","unstructured":"van Lierop, A. H. et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J. Bone Miner. Res. 26, 2804\u20132811. https:\/\/doi.org\/10.1002\/jbmr.474 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"73026_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/jmg.39.2.91","volume":"39","author":"W Balemans","year":"2002","unstructured":"Balemans, W. et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91\u201397. https:\/\/doi.org\/10.1136\/jmg.39.2.91 (2002).","journal-title":"J. Med. Genet."},{"key":"73026_CR16","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1517\/14712598.2014.920815","volume":"14","author":"S Minisola","year":"2014","unstructured":"Minisola, S. Romosozumab: from basic to clinical aspects. Expert Opin. Biol. Ther. 14, 1225\u20131228. https:\/\/doi.org\/10.1517\/14712598.2014.920815 (2014).","journal-title":"Expert Opin. Biol. Ther."},{"key":"73026_CR17","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948 (2016).","journal-title":"N. Engl. J. Med."},{"key":"73026_CR18","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N. Engl. J. Med. 377, 1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322 (2017).","journal-title":"N. Engl. J. Med."},{"key":"73026_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40265-019-01072-6","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham, A. Romosozumab: first global approval. Drugs 79, 471\u2013476. https:\/\/doi.org\/10.1007\/s40265-019-01072-6 (2019).","journal-title":"Drugs"},{"key":"73026_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.2106\/JBJS.L.00285","volume":"95","author":"MS Virk","year":"2013","unstructured":"Virk, M. S. et al. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J. Bone Joint Surg. Am. 95, 694\u2013701. https:\/\/doi.org\/10.2106\/JBJS.L.00285 (2013).","journal-title":"J. Bone Joint Surg. Am."},{"key":"73026_CR21","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1002\/jbmr.1984","volume":"28","author":"AD Taut","year":"2013","unstructured":"Taut, A. D. et al. Sclerostin antibody stimulates bone regeneration after experimental periodontitis. J. Bone Miner. Res. 28, 2347\u20132356. https:\/\/doi.org\/10.1002\/jbmr.1984 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"73026_CR22","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/0022034518766874","volume":"97","author":"M Liu","year":"2018","unstructured":"Liu, M. et al. Sclerostin and DKK1 inhibition preserves and augments alveolar bone volume and architecture in rats with alveolar bone loss. J. Dent. Res. 97, 1031\u20131038. https:\/\/doi.org\/10.1177\/0022034518766874 (2018).","journal-title":"J. Dent. Res."},{"key":"73026_CR23","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1089\/ten.TEA.2018.0013","volume":"24","author":"SH Yu","year":"2018","unstructured":"Yu, S. H. et al. Sclerostin\u2013Neutralizing antibody enhances bone regeneration around oral implants. Tissue Eng. A 24, 1672\u20131679. https:\/\/doi.org\/10.1089\/ten.TEA.2018.0013 (2018).","journal-title":"Tissue Eng. A"},{"key":"73026_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","volume":"96","author":"MS Ominsky","year":"2017","unstructured":"Ominsky, M. S., Boyce, R. W., Li, X. & Ke, H. Z. Effects of sclerostin antibodies in animal models of osteoporosis. Bone 96, 63\u201375. https:\/\/doi.org\/10.1016\/j.bone.2016.10.019 (2017).","journal-title":"Bone"},{"issue":"Suppl 1","key":"73026_CR25","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.injury.2007.02.010","volume":"38","author":"TW Axelrad","year":"2007","unstructured":"Axelrad, T. W., Kakar, S. & Einhorn, T. A. New technologies for the enhancement of skeletal repair. Injury 38(Suppl 1), S49-62. https:\/\/doi.org\/10.1016\/j.injury.2007.02.010 (2007).","journal-title":"Injury"},{"key":"73026_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s0142-9612(03)00528-3","volume":"25","author":"G Wei","year":"2004","unstructured":"Wei, G., Pettway, G. J., McCauley, L. K. & Ma, P. X. The release profiles and bioactivity of parathyroid hormone from poly(lactic-co-glycolic acid) microspheres. Biomaterials 25, 345\u2013352. https:\/\/doi.org\/10.1016\/s0142-9612(03)00528-3 (2004).","journal-title":"Biomaterials"},{"key":"73026_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.addr.2016.07.002","volume":"107","author":"A Jain","year":"2016","unstructured":"Jain, A. et al. Injectable formulations of poly(lactic acid) and its copolymers in clinical use. Adv. Drug Deliv. Rev. 107, 213\u2013227. https:\/\/doi.org\/10.1016\/j.addr.2016.07.002 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"73026_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1586\/erm.09.15","volume":"9","author":"JM Lu","year":"2009","unstructured":"Lu, J. M. et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn. 9, 325\u2013341. https:\/\/doi.org\/10.1586\/erm.09.15 (2009).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"73026_CR29","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/nprot.2015.063","volume":"10","author":"M Padial-Molina","year":"2015","unstructured":"Padial-Molina, M., Rodriguez, J. C., Volk, S. L. & Rios, H. F. Standardized in vivo model for studying novel regenerative approaches for multitissue bone\u2013ligament interfaces. Nat. Protoc. 10, 1038\u20131049 (2015).","journal-title":"Nat. Protoc."},{"key":"73026_CR30","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.bone.2015.08.007","volume":"81","author":"MS Ominsky","year":"2015","unstructured":"Ominsky, M. S. et al. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats. Bone 81, 380\u2013391. https:\/\/doi.org\/10.1016\/j.bone.2015.08.007 (2015).","journal-title":"Bone"},{"key":"73026_CR31","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.2106\/JBJS.K.00344","volume":"94","author":"AS Virdi","year":"2012","unstructured":"Virdi, A. S. et al. Sclerostin antibody increases bone volume and enhances implant fixation in a rat model. J. Bone Joint Surg. Am. 94, 1670\u20131680. https:\/\/doi.org\/10.2106\/JBJS.K.00344 (2012).","journal-title":"J. Bone Joint Surg. Am."},{"key":"73026_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jbmr.3581","volume":"34","author":"D Hadaya","year":"2019","unstructured":"Hadaya, D. et al. Clinically relevant doses of sclerostin antibody do not induce osteonecrosis of the jaw (ONJ) in rats with experimental periodontitis. J. Bone Miner. Res. 34, 171\u2013181. https:\/\/doi.org\/10.1002\/jbmr.3581 (2019).","journal-title":"J. Bone Miner. Res."},{"key":"73026_CR33","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/jbmr.2152","volume":"29","author":"MS Ominsky","year":"2014","unstructured":"Ominsky, M. S., Niu, Q. T., Li, C., Li, X. & Ke, H. Z. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J. Bone Miner. Res. 29, 1424\u20131430 (2014).","journal-title":"J. Bone Miner. Res."},{"key":"73026_CR34","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/jbmr.3038","volume":"32","author":"SW Kim","year":"2017","unstructured":"Kim, S. W. et al. Sclerostin antibody administration converts bone lining cells into active osteoblasts. J. Bone Miner. Res. 32, 892\u2013901. https:\/\/doi.org\/10.1002\/jbmr.3038 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"73026_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bonr.2018.03.001","volume":"8","author":"RW Boyce","year":"2018","unstructured":"Boyce, R. W. et al. Decreased osteoprogenitor proliferation precedes attenuation of cancellous bone formation in ovariectomized rats treated with sclerostin antibody. Bone Rep. 8, 90\u201394. https:\/\/doi.org\/10.1016\/j.bonr.2018.03.001 (2018).","journal-title":"Bone Rep."},{"key":"73026_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.addr.2012.09.004","volume":"64","author":"JM Anderson","year":"2012","unstructured":"Anderson, J. M. & Shive, M. S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 64, 72\u201382 (2012).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"73026_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/jbm.820190315","volume":"19","author":"G Visscher","year":"1985","unstructured":"Visscher, G. et al. Biodegradation of and tissue reaction to 50: 50 poly (DL-lactide-co-glycolide) microcapsules. J. Biomed. Mater. Res. 19, 349\u2013365 (1985).","journal-title":"J. Biomed. Mater. Res."},{"key":"73026_CR38","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1002\/jbm.a.34244","volume":"100","author":"PC Chang","year":"2012","unstructured":"Chang, P. C., Chung, M. C., Lei, C., Chong, L. Y. & Wang, C. H. Biocompatibility of PDGF-simvastatin double-walled PLGA (PDLLA) microspheres for dentoalveolar regeneration: a preliminary study. J. Biomed Mater. Res. A 100, 2970\u20132978. https:\/\/doi.org\/10.1002\/jbm.a.34244 (2012).","journal-title":"J. Biomed Mater. Res. A"},{"key":"73026_CR39","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1016\/j.biomaterials.2006.02.015","volume":"27","author":"XH Qu","year":"2006","unstructured":"Qu, X. H., Wu, Q., Zhang, K. Y. & Chen, G. Q. In vivo studies of poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) based polymers: biodegradation and tissue reactions. Biomaterials 27, 3540\u20133548. https:\/\/doi.org\/10.1016\/j.biomaterials.2006.02.015 (2006).","journal-title":"Biomaterials"},{"key":"73026_CR40","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.actbio.2017.10.043","volume":"65","author":"MA Washington","year":"2018","unstructured":"Washington, M. A. et al. Monomer sequence in PLGAmicroparticles: effects on acidic microclimates and in vivo inflammatory response. Acta Biomater. 65, 259\u2013271 (2018).","journal-title":"Acta Biomater."},{"key":"73026_CR41","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jconrel.2014.04.014","volume":"190","author":"M Santoro","year":"2014","unstructured":"Santoro, M., Tatara, A. M. & Mikos, A. G. Gelatin carriers for drug and cell delivery in tissue engineering. J. Control. Release 190, 210\u2013218 (2014).","journal-title":"J. Control. Release"},{"key":"73026_CR42","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1021\/acsami.7b18458","volume":"10","author":"Z Hu","year":"2018","unstructured":"Hu, Z., Ma, C., Rong, X., Zou, S. & Liu, X. Immunomodulatory ECM-like microspheres for accelerated bone regeneration in diabetes mellitus. ACS Appl. Mater. Interfaces 10, 2377\u20132390. https:\/\/doi.org\/10.1021\/acsami.7b18458 (2018).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"73026_CR43","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1517\/17425247.2011.568936","volume":"8","author":"EM Pritchard","year":"2011","unstructured":"Pritchard, E. M. & Kaplan, D. L. Silk fibroin biomaterials for controlled release drug delivery. Expert Opin. Drug Deliv. 8, 797\u2013811. https:\/\/doi.org\/10.1517\/17425247.2011.568936 (2011).","journal-title":"Expert Opin. Drug Deliv."},{"key":"73026_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jconrel.2012.10.015","volume":"165","author":"AN Ford Versypt","year":"2013","unstructured":"Ford Versypt, A. N., Pack, D. W. & Braatz, R. D. Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres\u2014a review. J. Control Release 165, 29\u201337. https:\/\/doi.org\/10.1016\/j.jconrel.2012.10.015 (2013).","journal-title":"J. Control Release"},{"key":"73026_CR45","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1902\/jop.2003.74.2.202","volume":"74","author":"QM Jin","year":"2003","unstructured":"Jin, Q. M., Anusaksathien, O., Webb, S. A., Rutherford, R. B. & Giannobile, W. V. Gene therapy of bone morphogenetic protein for periodontal tissue engineering. J. Periodontol. 74, 202\u2013213. https:\/\/doi.org\/10.1902\/jop.2003.74.2.202 (2003).","journal-title":"J. Periodontol."},{"key":"73026_CR46","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/gt.2008.174","volume":"16","author":"JA Cirelli","year":"2009","unstructured":"Cirelli, J. A. et al. AAV2\/1-TNFR: Fc gene delivery prevents periodontal disease progression. Gene Ther. 16, 426\u2013436. https:\/\/doi.org\/10.1038\/gt.2008.174 (2009).","journal-title":"Gene Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73026-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73026-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73026-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:36:54Z","timestamp":1670359014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-73026-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["73026"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-73026-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]},"assertion":[{"value":"20 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16217"}}